For research use only. Not for therapeutic Use.
Vebicorvir（Cat No.:I037992）is a potent investigational drug designed as a core protein allosteric modulator (CpAM) targeting hepatitis B virus (HBV). By disrupting the assembly and stability of HBV nucleocapsids, it inhibits viral replication at a critical stage, making it a promising candidate for treating chronic HBV infections. Vebicorvir has shown synergistic potential when combined with nucleos(t)ide analogs, offering a comprehensive approach to reducing viral load and improving treatment outcomes. Its novel mechanism represents an advanced strategy in HBV therapy, aiming for functional cure and enhanced patient care.
| Catalog Number | I037992 |
| CAS Number | 2090064-66-5 |
| Synonyms | Vebicorvir; ABI H0731; ABI-H0731; ABIH0731; ABIH 0731; ABIH-0731; ABI H 0731; ABI H-0731; |
| Molecular Formula | C19H12F3N3O4S2 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 6,11,11-trioxo-N-[[2-(trifluoromethyl)-1,3-thiazol-5-yl]methyl]-5H-benzo[b][1,4]benzothiazepine-3-carboxamide |
| InChI | InChI=1S/C19H12F3N3O4S2/c20-19(21,22)18-24-9-11(30-18)8-23-16(26)10-5-6-15-13(7-10)25-17(27)12-3-1-2-4-14(12)31(15,28)29/h1-7,9H,8H2,(H,23,26)(H,25,27) |
| InChIKey | LBJVBJYMZKEREY-UHFFFAOYSA-N |
| SMILES | C1=CC=C2C(=C1)C(=O)NC3=C(S2(=O)=O)C=CC(=C3)C(=O)NCC4=CN=C(S4)C(F)(F)F |
| Reference | 1: Huang Q, Cai D, Yan R, Li L, Zong Y, Guo L, Mercier A, Zhou Y, Tang A, Henne K, Colonno R. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01463-20. doi: 10.1128/AAC.01463-20. PMID: 32868329. |
